Avancées diagnostiques et thérapeutiques dans les lymphomes primitifs du système nerveux central

Hoang-Xuan, 2015, Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology, Lancet Oncol, 16, e322, 10.1016/S1470-2045(15)00076-5 Zouaoui, 2012, Recensement national histologique des tumeurs du système nerveux central : résultats généraux sur 40 000 cas, principales applications actuelles et perspectives, Neurochirurgie, 58, 4, 10.1016/j.neuchi.2012.01.004 Labreche, 2019, A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC network study, Pubmed Neuro Oncol, 10.1093/neuonc/noz088 Villano, 2011, Age, gender, and racial differences in incidence and survival in primary CNS lymphoma, Br J Cancer, 105, 1414, 10.1038/bjc.2011.357 Houillier, 2020, Management and outcome of primary CNS lymphoma patients in the modern era. A LOC network study, Neurology, 10.1212/WNL.0000000000008900 Guillevin, 2011, Imagerie multimodale par résonance magnétique des tumeurs cérébrales, Rev Neurol (Paris), 167, 704, 10.1016/j.neurol.2011.07.003 Baraniskin, 2011, Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system, Blood, 117, 3140, 10.1182/blood-2010-09-308684 Viaccoz, 2015, CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma, Neuro Oncol, 17, 1497, 10.1093/neuonc/nov092 Nguyen-Them, 2016, The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients, Eur J Cancer, 61, 69, 10.1016/j.ejca.2016.03.080 Costopoulos, 2016, IsoldSOLD: a new highly sensitive interleukin score for intraocular lymphoma diagnosis, Ophthalmology, 123, 1626, 10.1016/j.ophtha.2016.01.037 Gonzalez-Aguilar, 2012, Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas, Clin Cancer Res, 18, 5203, 10.1158/1078-0432.CCR-12-0845 Bruno, 2014, Mutational analysis of primary central nervous system lymphoma, Oncotarget, 5, 5065, 10.18632/oncotarget.2080 Bruno, 2018, Identification of novel recurrent ETV6-IgH fusions in primary central nervous system lymphoma, Neuro Oncol, 20, 1092, 10.1093/neuonc/noy019 Poulain, 2014, MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome, Br J Haematol, 167, 506, 10.1111/bjh.13078 Fontanilles, 2017, Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma, Oncotarget, 8, 48157, 10.18632/oncotarget.18325 Ferreri, 2016, Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial, Lancet Haematol, 3, e217, 10.1016/S2352-3026(16)00036-3 Bromberg, 2019, Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study, Lancet Oncol, 20, 216, 10.1016/S1470-2045(18)30747-2 Ferreri, 2017, Lancet Haematol, 4, e510, 10.1016/S2352-3026(17)30174-6 Houillier, 2019, Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study, J Clin Oncol, 37, 823, 10.1200/JCO.18.00306 Omuro, 2015, Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial, Lancet Haematol, 2, e251, 10.1016/S2352-3026(15)00074-5 Morris, 2013, Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome, J Clin Oncol, 31, 3971, 10.1200/JCO.2013.50.4910 Soussain, 2019, Eur J Cancer, 117, 121, 10.1016/j.ejca.2019.05.024 Ghesquieres, 2019, Ann Oncol, 30, 621, 10.1093/annonc/mdz032 Nayak, 2017, PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma, Blood, 129, 3071, 10.1182/blood-2017-01-764209 Abramson, 2017, Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma, N Engl J Med, 377, 783, 10.1056/NEJMc1704610